<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568291</url>
  </required_header>
  <id_info>
    <org_study_id>CTC01</org_study_id>
    <nct_id>NCT04568291</nct_id>
  </id_info>
  <brief_title>CTC in Lung Caner Patients With Bone Metastases</brief_title>
  <official_title>Clinical Reasearch on Three Dimensional Bionic Capture Network Circulating Tumor Cell in Lung Caner Patients With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Evaluate the feasibility of single cell sequencing technology based on three-dimensional&#xD;
           bionic capture network;&#xD;
&#xD;
        2. To build a risk prediction model of bone related events based on single cell sequencing;&#xD;
&#xD;
        3. To verify the risk prediction model of bone related events by single cell sequencing;&#xD;
&#xD;
        4. To verify the comprehensive treatment of non-small cell lung cancer ( NSCLC) bone&#xD;
           metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SREs（Skeletal related events）</measure>
    <time_frame>1 year</time_frame>
    <description>occurance of SREs，including bone pain, pathological fractures, spinal cord compression, hypercalcemia, and the need for surgery or radiotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Bone Metastases</condition>
  <condition>Single Cell Sequencing Technology</condition>
  <arm_group>
    <arm_group_label>routine treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>routine treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>model treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>model treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>model treatment</intervention_name>
    <description>the treatment decisions were decided by Machine Learning （ML） model in model treatment group</description>
    <arm_group_label>model treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>routine treatment</intervention_name>
    <description>the treatment decisions were decided by multi-disciplinary team （MDT）</description>
    <arm_group_label>routine treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-75 years&#xD;
&#xD;
          2. pathology-proven diagnosis of lung cancer and radiographical/pathological evidence of&#xD;
             BM&#xD;
&#xD;
          3. no previous treatment for BM&#xD;
&#xD;
          4. good general condition (Eastern Cooperative Oncology Group, ECOG Performance scores:&#xD;
             0-2) with an estimated survival time &gt; 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Sixth People'S Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Other (Non U.s.)</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hui zhao</last_name>
      <phone>13564460369</phone>
      <email>areyouwangzhiyu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Hui</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

